Home Health Index June Update
While the home health and post-acute care indices were marginally up in June, the S&P outperformed both by a significant margin.
There was plenty of regulatory and dealmaking news in the month, and that news likely affected stock prices in June and will most likely continue to affect stock prices moving forward.
First and foremost, the Centers for Medicare & Medicaid Services (CMS) released its proposed home health payment rule late in the month, which would — if finalized — reduce aggregate home health payments by 1.7% in 2025. CMS also proposed more permanent cuts to the Patient-Driven Groupings Model (PDGM).
This is now three consecutive years where CMS proposed cuts to home health payment.
There is some optimism that cuts can be mitigated through Congress or through legal action before Mom-and-Pop agencies suffer even more, yet much remains up in the air.
“Home health cuts were expected from providers, but the prospect of a third straight year with meaningful reductions in payment spells trouble,” says Joe Lynch, Partner and Managing Director at Stoneridge Partners. “It’s bad news for the public companies, of course. But they’ll likely be able to deal with the impact better, due to their scale. On the other hand, smaller providers will be affected more severely.”
The home health index was up 0.38% in June, while the post-acute care index was up 0.66%. Comparatively, the S&P was up 4.89% month over month.
Home Health Index
The home health proposed rule is a sign that CMS is not giving up on its theories and methodologies, despite vehement disagreement from providers.
Because fee-for-service revenue is generally the firm leg that providers stand on, there’s risk of industry destabilization.
After all, Medicare Advantage (MA) plans — which are becoming a larger payer source to home health providers by the day, due to MA penetration — generally pay far less for home health services.
Meanwhile, there was significant news regarding Amedisys Inc. (Nasdaq: AMED). The company agreed to offload a number of locations to VitalCaring. That deal is contingent upon the deal closing between UnitedHealth Group (NYSE: UNH) and Amedisys. At the same time, Amedisys likely decided to offload these locations in the first place to satisfy regulators concerned about antitrust in the wake of the UnitedHealth Group deal.
Once that divestment deal was agreed to, Amedisys’ stock went up. In June, Amedisys was up just slightly, but it continued to climb in the first days of July.
Meanwhile, Enhabit (NYSE: EHAB) continues to battle with the activist investor AREX Capital Management. The latter wants to replace the former’s board, citing financial underperformance.
Enhabit was down nearly 3% in June.
What comes next is the all-important August annual meeting. That’s where the showdown between Enhabit, which wants to keep its current board, and AREX Capital will come to a head.
Enhabit released some of its earnings somewhat early in July as a way to point to its recent progress.
“Overall, the second quarter of 2024 is on track to mark Enhabit’s third consecutive quarter of business stabilization and successfully positioning the Company for profitable growth,” Enhabit CEO Barb Jacobsmeyer said in a statement. “This momentum underscores the strength of our strategy, disciplined approach to debt reduction and commitment to stockholder value creation.”
Post-Acute Care Index
The Pennant Group (Nasdaq: PNTG), which has consistently and steadily risen over the past year, was down slightly in June.
But that was not due to lack of activity.
In fact, the company is headed eastward for the first time after agreeing to a partnership with Connecticut-based Hartford HealthCare.
Pennant will take over Hartford’s home health and hospice operations, which will greatly expand its footprint. The company previously did not have locations east of Wisconsin.
“We have deep admiration for Hartford HealthCare and the commitment to home-based care it has long demonstrated through HHCAH,” Pennant CEO Brent Guerisoli said in a press statement. “We are thrilled to collaborate with Hartford HealthCare and contribute home health and hospice expertise to Hartford HealthCare’s impressive integrated care system. Hartford’s selection of Pennant is an honor and testament to the effectiveness of our unique operating model that empowers local leaders to transform operations and provide life-changing service in their communities.”
Pennant continues to remain extremely acquisitive.
The same goes for Addus Homecare Corp. (Nasdaq: ADUS), which was up slightly in June, and BrightSpring Health Services (Nasdaq: BTSG), which was also up about 1%.
Aveanna Healthcare Holdings (Nasdaq: AVAH) has been less acquisitive in comparison to its post-acute index peers, but was up the most in June – by 5.75%.
Quote of the Month
“We know nature plays an important role in human health, but behavioral health and health care providers often neglect to think about it as an intervention.” Lead Researcher Joanna Bettmann, a professor at the University of Utah College of Social Work.
Read the Full Article Here: Natural Medcine: Head Outside for Better Mental Health
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
- Amedisys (AMED)
- Enhabit (EHAB)
Here are the results of the stock prices for the past two years:
Company | 6/30/24 | 1 mos change | YTD change | 6/30/23 | 6/30/22 |
Amedisys | 91.80 | +0.71% | -3.43% | 91.44 | 105.12 |
Enhabit | 8.92 | -2.94% | -13.82% | 11.50 | – |
HH Index* | 50.36 | +0.38% | -4.45% | 51.47 | 130.43 |
S&P | 5535.75 | +4.89% | +16.06% | 4450.38 | 3785.38 |
Enterprise Value (EV)
EV (in M) | 2024 | 2023 | 2022 |
Amedisys | 3380 | 3420 | 4210 |
Enhabit | 1020 | 1180 | – |
HH Index Total | 4400 | 4600 | 9890 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2024 | 2023 | 2022 |
Amedisys | 150% | 153% | 189% |
Enhabit | 97% | 111% | – |
HH Index Average* | 124% | 132% | 220% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these seven publicly traded post-acute care companies, all listed on the NASDAQ:
- Aveanna (AVAH)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Enhabit (EHAB)
- Brookdale Senior Living Inc. (BKD)
- Brightspring (BTSG)
Here are the results of the Post-Acute stock prices for the past two years:
Company | 6/30/24 | 1 mos change | YTD change | 6/30/23 | 6/30/22 |
---|---|---|---|---|---|
Amedisys | 91.80 | +0.71% | -3.43% | 91.44 | 105.12 |
Addus | 116.11 | +1.13% | +25.05% | 92.70 | 83.28 |
Pennant | 23.19 | -1.49% | +66.59% | 12.28 | 12.81 |
Brookdale | 6.83 | +1.79% | +1.79% | 4.22 | 4.54 |
Enhabit | 8.92 | -2.94% | -13.82% | 11.50 | 22.97 |
Brightspring
Aveanna |
11.36
2.76 |
+0.98%
+5.75% |
–
+2.99% |
–
1.69 |
–
2.26 |
Enterprise Value (EV)
EV (in M) | 2024 | 2023 | 2022 |
---|---|---|---|
Amedisys | 3380 | 3420 | 4210 |
Addus | 2150 | 1600 | 1580 |
Pennant | 1040 | 689 | 703 |
Brookdale | 574 | 522 | 564 |
Enhabit | 1020 | 1180 | – |
Brightspring
Aveanna |
4780
1830 |
–
1640 |
–
– |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2024 | 2023 | 2022 |
---|---|---|---|
Amedisys | 150% | 153% | 189% |
Addus | 198% | 164% | 178% |
Pennant | 181% | 142% | 157% |
Brookdale | 189% | 185% | 210% |
Enhabit | 97% | 111% | – |
Brightspring
Aveanna |
51%
95% |
–
91% |
–
– |
This graph displays 24 months of Post-Acute Care Index performance.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Yahoo Finance. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index June 2024 | Stoneridge Partners)
Recent Transactions From Around The Country
- NeuroFlow acquired Owl, a provider of measurement-based behavioral health care.
- Bristol Hospice has acquired Mississipi-based Mid-Delta Hospice.
SOLD by Stoneridge!!!
- Stoneridge Partners is proud to announce the successful sale of a Home Hare Agency in Kansas
- Stoneridge Partners is proud to announce the successful sale of a Healthcare Company in Pennsylvania
View Stoneridge closed transactions on our Website.
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Medicaid/Medicare home health & home care company. $2.5M in revenue. Well-established. Stable revenue. Profitable year-over-year.
I/DD provider. $2.6M+ in revenue with 19% EBITDA margins. CARF accredited, long history in the community. Mix of county contracts and Medicaid payors. Consistently recognized...
Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.
Designer/Distributor of innovative, therapeutic, health and wellness personal products. $1.5M+ in revenue. Launched in the US and UK, now launching into the EU. Nearly 7,000...
Staffing Agency licensed to provide staffing services in 6 states. $ 2.4M+ in LTM revenue. Significant long-term contracts with providers in the Care-At-Home space, Health...
Homecare agency. $6.5M+ in revenue. Located on Long Island. Blend of Private Duty & Medicaid patients.
Large home care franchisee. $26M+ in revenue. 89% Medicaid. Well-established company operating over 20 years. Phenomenal year-over-year revenue growth.
Maricopa County hospice. 40+ ADC. CHAP accredited. No CAP or regulatory issues.
Non-medical home care agency. $1M+ revenue with 15%+ AEBITDA. 60% Medicaid/30% Private Pay/10% VA. 35% Consumer-Directed Care.
Growing ABA (Autism) therapy clinic established in 2020. $1.6M in revenue. Market demand heavily outweighs supply in the area for ABA therapy.
Well-established private pay agency in the Denver area. $ 2M in revenue. Profitable. Diverse list of referral sources.
Eastern Oklahoma home health agency. $2M in revenue with 15%+ AEBITDA. 70% Medicare/30% VA.
Northeast Oklahoma home health company. $1.7M of revenue and profitable. 95% traditional Medicare. Long history in the area.
Special education and tutorial provider with limited access contracts. $3M in revenue. Strong relationships with county school programs. Long history in the community, close to...
Growing ABA (Autism) therapy clinic established in 2016. $ 3.1M in revenue. Huge Opportunities for expansion in a thriving market. BHCOE (Behavioral Health Center of...
Medical practice - Region 10. $2.6M in revenue. Private practice with multiple profit centers.
Medicare-certified home health agency. $1.7M in revenue. AHCA accredited. Broward County (Region 10)
Growing Medicare home health and hospice organization. $17M+ in revenue. Over 25 years in business. A well-established leader in the market.
Medicare-certified home health agency. Region 7, including sought-after Orange county (Orlando). Minimal census.
ABA (Autism) therapy. $1M in revenue. Facility-based. Profitable business with demand exceeding supply.
$8+ million in revenue. Long-established Ohio home health and hospice. Extensive history of clinical excellence. CHAP accredited. Fully staffed
Medicare-certified home health agency. $1.3M in revenue. Accredited. 90%+ VA. North Orange and LA counties.
Home health agency. Opportunity to establish a presence in Tennessee. Covers Davidson (Nashville) and 8 surrounding counties. Certificate of need - very rare in Tennessee.
Behavioral health services. $25+M in revenue. Residential care facilities, inpatient psych/outpatient mental health support services, and counseling for adults and elderly patients. Platform opportunity with...
Skilled home health agency. Servicing Central Florida for over 20 years. Census approximately 35.
Houston-based home health company. $7+M in revenue. Profitable. Well established within the community. Showing positive growth trends.
Occupational therapy practice with 2 offices in Southern California. Hand and upper extremity specialists. 20-plus years in the community. Strong referral relationships. Management and staff...
Hospice. 100+ ADC. Accredited. No CAP or regulatory issues.
$5M in revenue. Located in Northern/Richmond VA. Health system-owned Medicare home health and hospice. Growing organization.
Medicare-certified home health. Opportunity to establish home health presence in Texas. Minimal census.
$4.5+M Houston-based Medicaid home care company. Established 13 years ago. Excellent HHSC contracts are in place, resulting in an impressive bottom line. Fully staffed.
Non-medical home care franchise. $2M in revenue. 60% private pay. 20% EBITDA. Houston market.
Medicare/Medicaid-certified home health agency. $1.4M in revenue. District 9. Profitable. Accredited.
Home care agency. $30M+ in revenue. 95% Medicaid. Platform opportunity.
Hospice. 45+ ADC. Rio Grande Valley. No CAP or regulatory issues.
Profitable private-duty home health agency in Northern Virginia. $1.5M in revenue. 20+ years in the community.
Home Health / Virginia / Popular
Profitable home care franchise with consistent sales growth. Revenue of $1.3M. Great reputation within the community.
$40M+ home care agency with 20+% AEBITDA. Primarily private-duty, non-medical (90%). Medicaid waiver programs. 40% family caregivers. Multiple locations.
Home Care / Pennsylvania / Popular
Medical Staffing Agency. $4.6M in revenue. Established over 25 years. Excellent rapport with regional hospital network.
Medicare-certified home health agency. Houston-area. Minimal census.
Home Health / Texas / Popular
Medicare-certified home health agency. District 3. Approximately $700k in revenue. Accredited.
Home Health / Florida / Popular
Home Health Index June 2024 | Stoneridge Partners
From Joe Lynch, Publisher of “Home Health Index.” Joe can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index.
Joe Lynch, Partner and Managing Director at Stoneridge Partners brings over 30 years of healthcare expertise, specializing in mergers and acquisitions, finance, regulatory compliance, and business development. After earning his Business Administration degree from the University of Mississippi, Joe helped expand OrNda Healthcorp’s (now Tenet’s) home health care division.
In 1997, Joe founded Reachout Home Care, a Medicare and private duty agency, which he grew into three operating companies in Dallas and Houston before selling to Humana in 2014 using Stoneridge Partners. After the sale of his own company Joe joined Stoneridge, and for the last ten years has used his industry knowledge to help other owners list their companies and bring them to a successful close. With a proven track record in operations and M&A, Joe brings unmatched experience and
professionalism to every transaction.
For more information, please contact Joe directly at 214-394-0070 or [email protected]. All communications are confidential.